HealthTree Podcast for Multiple Myeloma cover image

HealthTree Podcast for Multiple Myeloma

Latest episodes

undefined
Aug 24, 2016 • 1h 6min

Myeloma Crowd Radio: MCRI Update with Michael Hudecek, MD

One year ago, we began raising funds for the Myeloma Crowd Research Iniatiive. With the help of an expert Scientific Advisory Board and a knowledgeable Patient Advisory Board, we selected two projects to fund: 1) a CAR T Cell research project targeting CS1 and BCMA from Drs. Hermann Einsele and Michael Hudecek from the University of Würzburg in Germany and 2) a T cell immunotherapy using marrow infiltrating lymphocytes (MILs) with transplant from Dr. Ivan Borrello of Johns Hopkins.  We've now provided an initial $100,000 to each research project. In this episode, Dr. Michael Hudecek gives us an update of his CAR T cell research from the grant award that the Myeloma Crowd Research Initiative has provided. Learn more about what we've done with YOUR support to help advance a cure in this important episode.
undefined
Aug 3, 2016 • 1h 5min

Myeloma Crowd Radio: Dr. Philip McCarthy, Roswell Park Cancer Institute

Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies showing greater overall survival and with new drugs and immunotherapies in the mix, what can we add on the front or back end to make transplant even better? Hear from Dr. Philip McCarthy from the Roswell Park Cancer Institute, a stem cell transplant expert, about the use of maintenance treatments and up-front options that can give patients more durable outcomes.
undefined
Jul 15, 2016 • 58min

Myeloma Crowd Radio: Using Nanotechnology in Multiple Myeloma

Nanotecnology is the study of very small things - won to the atom and molecule level. Researchers at Washingon University have been given a prestigious grant by the NIH to study nanotechnology in cancer and more specifcially, in multiple myeloma. Nanotechnology can deliver a higher concentration (by a hundred fold) of drug in a more targeted way. It can also usie imaging testing (like PET/CT) and MRI to find and selectively target cancerous cells. It can also help kick hiding myeloma cells out into the blood which can then be killed by myeloma drugs. This is a groundbreaking use of new technolgoy in cancer with a team of top experts.
undefined
Jun 10, 2016 • 1h 23min

Myeloma Crowd Radio: Dr. Don Benson, Ohio State University

You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they are best used from Dr. Don Benson, MD, PhD, an immunotherapy expert who has been actively researching this type of therapy for many years.
undefined
May 24, 2016 • 1h 26min

Myeloma Crowd Radio: ICER President Steven D. Pearson, MD, MSc

The Institute for Clinical and Economic Review’s (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis “to discuss the comparative clinical effectiveness and value of therapies of multiple myeloma.”  The goal is to create recommendations that health insurers (or payers) will use to determine reimbursement levels for drugs used in myeloma treatment.  Since the public announcement of ICER’s plan in February 2016, the draft reports have been strongly criticized by myeloma specialists, pharmaceutical companies, and more recently, patient advocates.  Steven Pearson will discuss ICER’s perspective, addressing critics of ICER’s methodology, process, definitions of value, and, as of now, the lack of inclusion of patient views.
undefined
May 13, 2016 • 1h 11min

Myeloma Crowd Radio: Dr. Jacob Laubach, MD, MPP, Dana Farber Cancer Institute

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they continue to be developed and how they are being used in quad combinations with immunotherapies to fight myeloma. Dr. Jacob Laubach shares how they differ, who they work best for (and don't), when they should be used as maintenance therapy and how a new gene may give us clues into who will respond and who will not.  Thanks to our episode sponsor, Takeda Oncology.
undefined
May 6, 2016 • 1h 20min

Myeloma Crowd Radio: Dr. William Matsui, MD, Johns Hopkins Kimmel Cancer Center

Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may not affect the myeloma stem cells. Dr. Matsui recently presented results from a study he did with colleagues at Johns Hopkins testing a new monoclonal antibody with lenalidomide and dex. Just with len/dex, he saw myeloma stem cells increase by 2.5 times, but when the new monoclonal antibody was added, it decreased the myeloma stem cells by half. Learn more about this up and coming new target in clinical trials that can kill myeloma cells at their source.
undefined
Apr 26, 2016 • 1h 12min

Myeloma Crowd Radio: Melanie House, DPT, NCS, University of Iowa

Melanie House, DPT, NCS of the University of Iowa recently presented at Pat's Myeloma Survival School on physical issues that myeloma patients face before, during and after their treatment. As part of the Muscles for Myeloma series, she will give practical, real-world advice to make life more manageable for patients: How to rebuild strength during and after treatment and how dex and bedrest waste musclesHow to prevent falls and improve balanceHow to manage peripheral neuropathyHow to increase enduranceHow to overcome that "so tired" feeling of fatigue post-treatmentWhat to do about shortness of breathHow to decrease back pain, muscles spasms and nerve pain Thanks to our episode sponsor, Takeda Oncology Thanks also to our Muscles for Myeloma sponsors: Sanofi Genzyme, Takeda Oncology and Celgene Corporation
undefined
Apr 15, 2016 • 1h 10min

Myeloma Crowd Radio: Dr. David Siegel, MD, PhD, John Theurer Cancer Center

The multiple myeloma aresenal is growing, giving myeloma experts more tools to combat the complex blood cancer, multiple myeloma. Learn how investigators like Dr. David Siegel, MD, PhD of the John Theurer Cancer Center are vetting treatment combinations using clinical trials to identify optimal treatment paths, especially for patients who are facing relapses or who have become refractory to existing medications.  Thanks to our episode sponsor, Takeda Oncology.
undefined
Mar 29, 2016 • 31min

Myeloma Crowd Radio: Dr. Irene Ghobrial, MD, Dana Farber Cancer Institute

Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are waiting until progression to treat when we have newer non-toxic therapies to use. Dr. Ghobrial shares her Prevention of Progression Clinic's efforts to keep myeloma at bay. In this show, she shares her open study (observational) that includes all MGUS and smoldering myeloma patients. It's easy to join - just mail her blood and marrow samples when you have your regular testing done and they will keep track of how progression happens and why.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode